Category: Insulin

Novo Nordisk Logo

Novo Nordisk’s New Insulin Pen for Children Wins GOOD DESIGN Award

The Chicago Athenaeum Museum of Architecture and Design in cooperation with The European Centre for Architecture, Art, Design and Urban Studies have chosen to award Novo Nordisk a 2010 GOOD DESIGN™ Awardfor the NovoPen Echo, a new insulin pen designed specifically with the needs of children in mind...
0 Shares
mannkind-logo

FDA Rejects Afrezza, Mannkind’s Inhaled Insulin

The FDA's Center for Drug Evaluation and Research has issued a complete response letter to Mannkind corp. regarding the New Drug Application (NDA) for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes...
0 Shares
Biocon logo

Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients

Biocon Ltd., India's largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes. The study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo...
0 Shares
MonoSol Rx - logo

Positive Results for Oral Insulin Delivery in Pre-Clinical Trials

MonoSol Rx and Midatech Group Ltd. anounced positive results from pre-clinical proof-of-concept studies for oral insulin delivery in Rhesus monkey studies and hope to begin human trials in 2011. The two companies are developing insulin PharmFilm under a partnership that leverages MonoSol Rx’s...
0 Shares
mannkind-logo

FDA Informs Mannkind It Needs More Time to Review AFREZZA NDA

The FDA informed MannKind Corporation that it would not be able to complete the review of the New Drug Application (NDA) for AFREZZA (insulin human [rDNA origin]) Inhalation Powder by the action date of December 29, 2010. The FDA stated that it will require approximately four additional weeks to complete its review of the NDA...
0 Shares
NovoNordiskLogo

New Novo Nordisk Insulin Reduces Risk of Nighttime Hypoglycemia, New Studies Show

Novo Nordisk's ultra long-acting basal insulin Degludec significantly reduces risk of hypoglycemia during the night compared to insulin glargine, according to two long-term studies. The company announced the clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes...
0 Shares
NovoNordiskLogo

Novo Nordisk to Develop Oral Insulin

Novo Nordisk has announced the signing of an exclusive Development and Licence Agreement with Emisphere Technologies, Inc. to develop and commercialize oral formulations ofNovo Nordisk’s insulins. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed...
0 Shares